# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Flannery O'Connor (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML046-SYN
- Date: 2026-04-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Augusta Pemberton-Diallo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results of the lupus tests; rheumatology consultation today. **S**

## History of present illness

Ms. O'Connor returns nine days after presenting with three months of painful, swollen hands, wrists, and knees, evening fevers, fatigue, a facial rash after sun, and protein and blood in her urine. She saw Dr. Okonjo-Strand this morning, and the tests drawn there returned this afternoon: ANA positive at 1:640 in a homogeneous pattern, anti-dsDNA 186 IU/mL, anti-Sm 42 U/mL, and low complements (C3 62, C4 8 mg/dL). Anticardiolipin and anti-beta-2 glycoprotein I antibodies are negative and the lupus anticoagulant test is negative. The urine protein-to-creatinine ratio is 1.8 g/g, with 22 red cells per high-power field, many of them misshapen, and a red cell cast; creatinine is 0.8. Hepatitis B surface antigen is negative with a positive surface antibody, and hepatitis C and HIV tests are negative; a pregnancy test is negative. Before the results were given she was asked how she wanted to hear them and said she wanted all of it, at once. She was told directly that she has systemic lupus erythematosus, that the urine findings mean the kidneys are probably involved, and that a kidney biopsy is needed to choose treatment; she knows that her father had lupus, and was told plainly that treatment and outlook today are very different. She repeated it back accurately. She asked that her diagnosis not be shared with anyone she has not named. **S**

| Element | Detail |
|---|---|
| Serology | ANA 1:640 homogeneous; anti-dsDNA 186; anti-Sm 42; C3 62, C4 8; antiphospholipid antibodies and lupus anticoagulant negative |
| Kidney | Protein-to-creatinine ratio 1.8 g/g; active sediment with a red cell cast; creatinine 0.8 |
| Infection screening | Hepatitis B immune by vaccination; hepatitis C and HIV negative |
| Disclosure | Told the diagnosis directly; teach-back correct; privacy request recorded |
| Coordination | Rheumatology seen this morning; kidney biopsy in two days |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Evening fevers to 37.8 °C and fatigue |
| Musculoskeletal | Positive | Painful, swollen hand joints and knees; an hour of morning stiffness |
| Integumentary | Positive | Facial rash after sun; some hair shedding |
| Ears, nose, mouth, and throat | Positive | A painless sore on the roof of the mouth |
| Respiratory | Negative | No pleuritic chest pain or breathlessness |
| Genitourinary | Negative | No foamy urine noticed; no swelling of the legs |
| Psychiatric | Positive | Worried but composed; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a day **S**
- Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term **S**
- Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/84 mmHg; pulse 92 bpm; respirations 16/min; temperature 37.6 °C; oxygen saturation 98% on room air; weight 59.6 kg; BMI 21.1 kg/m². All vital signs are synthetic.

ANA titer (HEp-2 immunofluorescence): 640 (high); Anti-dsDNA: 186 [IU]/mL (high); Anti-Sm: 42 U/mL (high); Complement C3: 62 mg/dL (low); Complement C4: 8 mg/dL (low); Anticardiolipin IgG: 6 U/mL; Anticardiolipin IgM: 4 U/mL; Anti-beta-2 glycoprotein I IgG: 3 U/mL; Anti-beta-2 glycoprotein I IgM: 2 U/mL; Lupus anticoagulant (dRVVT screen-to-confirm ratio): 1.04; Urine protein-to-creatinine ratio: 1.8 g/g (high); Urine red cells: 22 /[HPF] (high); Creatinine: 0.8 mg/dL; eGFR: 101 mL/min/1.73 m². All results are synthetic.

## Change since baseline

- Urine protein-to-creatinine ratio: 1.6 g/g (high) at baseline, 1.8 g/g (high) at this visit **S**
- Urine red cells: 18 /[HPF] (high) at baseline, 22 /[HPF] (high) at this visit **S**
- Creatinine: 0.8 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- eGFR: 101 mL/min/1.73 m² at baseline, 101 mL/min/1.73 m² at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Tired but engaged; temperature 37.6 °C |
| Skin | Red, slightly raised rash over both cheeks and the bridge of the nose, sparing the nasolabial folds; diffuse thinning of the scalp hair |
| Mouth | Painless 4 mm ulcer on the hard palate |
| Musculoskeletal | Synovitis of the second and third knuckles and middle finger joints of both hands and both wrists; small knee effusions |
| Cardiovascular | No rub; no edema |
| Respiratory | Clear; no rub |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Systemic lupus erythematosus** (M32.19). The positive ANA meets the entry criterion, and the EULAR/ACR weighted classification criteria add up to 32 (fever 2, thrombocytopenia 4, acute cutaneous lupus 6, joint involvement 6, proteinuria above 0.5 g a day 4, low C3 and C4 4, anti-dsDNA or anti-Sm 6), well above the threshold of 10. The disease is highly active (SLEDAI-2K 23). Antiphospholipid antibodies are negative, which matters for contraception and any future pregnancy. This is lupus, not rheumatoid arthritis. **S**
   - Hydroxychloroquine 300 mg daily now (5 mg/kg), long term.
   - Sun protection every day.
   - No NSAIDs with kidney involvement; acetaminophen for pain.
   - Pneumococcal PCV20 and recombinant zoster vaccine dose 1 today, before immunosuppression.
2. **Proteinuria with an active urine sediment** (R80.9). Protein-to-creatinine ratio 1.8 g/g with dysmorphic red cells and a red cell cast: lupus nephritis is likely, and the class determines treatment. Blood pressure 136/84 is above the target of 130/80. **S**
   - Ultrasound-guided kidney biopsy in two days.
   - Losartan 25 mg daily for proteinuria and blood pressure; potassium and creatinine in two to four weeks.
3. **Contraception before immunosuppression**. Mycophenolate, the likely treatment, causes birth defects and needs highly effective contraception. With negative antiphospholipid antibodies estrogen-containing methods are not ruled out, but with active disease she chose a levonorgestrel intrauterine system. **S**
   - Intrauterine system inserted before treatment starts.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Classification: ANA and the EULAR/ACR criteria | At diagnosis | Completed today | ANA 1:640; criteria score 32 |
| Laboratory | Anti-dsDNA, anti-Sm, C3, and C4 | At diagnosis, then every 3 months while active | Completed today | Anti-dsDNA 186, anti-Sm 42, C3 62, C4 8 |
| Laboratory | Antiphospholipid antibodies and lupus anticoagulant | At diagnosis | Completed today | Anticardiolipin IgG 6 and IgM 4, anti-beta-2 glycoprotein I IgG 3 and IgM 2, dRVVT ratio 1.04: all negative |
| Laboratory | Urine protein-to-creatinine ratio and urine sediment | At diagnosis, then every 3 months | Completed today | 1.8 g/g; 22 red cells per high-power field with dysmorphic cells and a red cell cast |
| Laboratory | Creatinine and eGFR | At diagnosis, then every 3 months | Completed today | Creatinine 0.8, eGFR 101 |
| Laboratory | Blood count | At diagnosis | Up to date | Nine days ago: white cells 3.3, lymphocytes 0.8, hemoglobin 11.0, platelets 138 |
| Imaging | Kidney biopsy | When proteinuria is 0.5 g/g or more, or with an active sediment | Ordered | Booked in two days |
| Laboratory | Hepatitis B, hepatitis C, and HIV screening before immunosuppression | Before immunosuppression | Completed today | Hepatitis B surface antigen negative, surface antibody positive; hepatitis C and HIV negative |
| Medication safety | Vaccinations before immunosuppression | Before immunosuppression when possible | Completed today | PCV20 and recombinant zoster dose 1 today; influenza given in October; COVID-19 due |
| Medication safety | Hydroxychloroquine dose and baseline eye examination | Dose at start; eye examination within the first year | Due | 300 mg daily, 5 mg/kg; ophthalmology booked |
| Examination | Blood pressure | Every visit | Completed today | 136/84 mmHg, above target; losartan started |
| Medication safety | Pregnancy test and contraception before mycophenolate | Before the first dose | Ordered | Pregnancy test negative today; intrauterine system booked |
| Self-management | Disclosure and shared decisions | At diagnosis and with every result | Completed today | Told directly; teach-back correct; written summary given |
| Self-management | Sun protection | Every visit | Completed today | Sunscreen SPF 50, a hat, and midday shade |
| Survey | Depression screen (PHQ-9) | At diagnosis, then periodically | Up to date | PHQ-9 7 nine days ago; supportive care |

## Goal progress

- Establish the diagnosis within two weeks and hear it directly, in plain words. Outcome by 2026-04-22: Told directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summary. **S**
- Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months. In progress; target 2026-10-26. **S**
- Prednisone 5 mg a day or less by six months, with withdrawal considered later. In progress; target 2026-10-26. **S**
- Write at least four mornings a week through treatment. In progress; target 2026-12-31. **S**
- No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines. In progress; target 2026-12-31. **S**

## Medication changes

- Started: Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long term **S**
- Started: Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressure **S**

## Guideline basis

- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71(9):1400-1412 (2019), EULAR and American College of Rheumatology
- EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83(1):15-29 (2023), EULAR
- 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol 2025;77(9):1115-1135 (2024), American College of Rheumatology
- 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2023;75(3):333-348 (2022), American College of Rheumatology
- 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res 2020;72(4):461-488 (2020), American College of Rheumatology

## Follow-up

- Kidney biopsy in two days; intrauterine system next week; primary care review with the biopsy result in one week. **S**
- Next scheduled visit 2026-04-29: kidney biopsy result: class III lupus nephritis; start of pulse methylprednisolone, prednisone, mycophenolate, and belimumab. **S**
